$IMUC news!! ImmunoCellular Therapeutics issues a letter to shareholders on its progress in advancing ICT-107 to a Phase 3 Registrational Trial (IMUC) :
Co stated: "ICT-107 is advancing to its final stage of development. Reaching agreement with the FDA on the Special Protocol Assessment is a significant achievement and means we have lower regulatory risk than completing phase 3 without this up-front FDA review. We are positioned to initiate clinical trial sites within 3 months in the US, with plans to enroll the first patient in the trial soon thereafter."
News 
Market Data 
Discover 
